Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frampton

Showing results (81-90 of 2,541) with videos related to

Pageof 255
Sort By:
CNS Drugs|January 16, 2021
Correction to: OnabotulinumtoxinA in Chronic Migraine: A Profile of Its UseJames E Frampton
Drugs|December 1, 2021
Correction to: Efmoroctocog Alfa: A Review in Haemophilia AJames E Frampton
Targeted Oncology|October 8, 2021
Correction to: Isatuximab: A Review of Its Use in Multiple MyelomaJames E Frampton
Drugs|September 20, 2018
Tafenoquine: First Global ApprovalJames E Frampton
Drugs|July 31, 2020
Inebilizumab: First ApprovalJames E Frampton
Drugs|October 11, 2012
Aclidinium: in chronic obstructive pulmonary diseaseJames E Frampton
Drugs|September 14, 2021
Finerenone: First ApprovalJames E Frampton
Drugs|August 19, 2023
Epcoritamab: First ApprovalJames E Frampton
Drugs|November 18, 2010
Olanzapine long-acting injection: a review of its use in the treatment of schizophreniaJames E Frampton
Drugs|August 25, 2010
Tapentadol immediate release: a review of its use in the treatment of moderate to severe acute painJames E Frampton
Pageof 255

Showing results (81-90 of 2,541) with videos related to

Sort By:
Pageof 255
CNS Drugs|January 16, 2021
Correction to: OnabotulinumtoxinA in Chronic Migraine: A Profile of Its UseJames E Frampton
Drugs|December 1, 2021
Correction to: Efmoroctocog Alfa: A Review in Haemophilia AJames E Frampton
Targeted Oncology|October 8, 2021
Correction to: Isatuximab: A Review of Its Use in Multiple MyelomaJames E Frampton
Drugs|September 20, 2018
Tafenoquine: First Global ApprovalJames E Frampton
Drugs|July 31, 2020
Inebilizumab: First ApprovalJames E Frampton
Drugs|October 11, 2012
Aclidinium: in chronic obstructive pulmonary diseaseJames E Frampton
Drugs|September 14, 2021
Finerenone: First ApprovalJames E Frampton
Drugs|August 19, 2023
Epcoritamab: First ApprovalJames E Frampton
Drugs|November 18, 2010
Olanzapine long-acting injection: a review of its use in the treatment of schizophreniaJames E Frampton
Drugs|August 25, 2010
Tapentadol immediate release: a review of its use in the treatment of moderate to severe acute painJames E Frampton
Pageof 255